Review of ongoing clinical trials in non-small cell lung cancer: A status report for 2009 from the Website

Janakiraman Subramanian, Anusha R. Madadi, Monica Dandona, Kristina Williams, Daniel Morgensztern, Ramaswamy Govindan

Research output: Contribution to journalArticlepeer-review

32 Scopus citations


Introduction: Several new agents are being tested in clinical trials for patients with non-small cell lung cancer (NSCLC). A survey of ongoing clinical trials in NSCLC in the website would help identify areas that require further attention in the future. Methods:We conducted a survey of ongoing clinical trials on NSCLC registered in the website. The advanced search option was applied using the terms "non small cell lung cancer," "open studies," "interventional," and "adults 18 years or older." Results: Of the 493 eligible trials, 77 (15.6%) were phase III, 92 (18.7%) were phase I, and 240 (48.7%) were phase II trials. Universities were listed as the primary sponsor for 224 (45.4%) trials and pharmaceutical industry for 166 (33.7%) trials. Majority of the trials were multicenter studies (56.8%) and were being conducted exclusively within the United States (51.3%). A large proportion of phase II and III clinical trials (77.2%) were focused on patients with advanced-stage disease. The most frequently used end points were progression-free survival (27.1%) followed by tumor response rate (22.9%) and overall survival (16.6%). Although biomarker analysis was included in 185 (37.5%) trials, only 39 (7.9%) trials used biomarkers for patient selection. Conclusions: Progression-free survival is the end point most commonly used to assess the effectiveness of experimental regimens, and biomarker-based patient selection is rarely used in ongoing clinical trials for NSCLC.

Original languageEnglish
Pages (from-to)1116-1119
Number of pages4
JournalJournal of Thoracic Oncology
Issue number8
StatePublished - Aug 2010


Dive into the research topics of 'Review of ongoing clinical trials in non-small cell lung cancer: A status report for 2009 from the Website'. Together they form a unique fingerprint.

Cite this